Atnahs to launch €58 million add-on term loan, repricing on Monday

By Sara Rosenberg

New York, Feb. 12 – Atnahs Pharma (Antigua Bidco Ltd.) is scheduled to hold a lender meeting on Monday to launch a €58 million add-on term loan B due Aug. 7, 2026 and a repricing/refinancing of its existing €614 million term loan B due Aug. 7, 2026, according to a market source.

Barclays and Credit Suisse are the physical bookrunners on the deal. Other bookrunners include HSBC, KKR Capital Markets, Investec Bank, MUFG, Jefferies and NatWest Markets.

Price talk on the term loan debt is Euribor plus 425 basis points to 450 bps with a 0% floor and an original issue discount of 99.75, the source said.

The term loan debt is getting 101 soft call protection for six months.

Existing lenders are being offered cashless roll, the source continued.

Proceeds from the add-on term loan will be used to repay revolving credit facility borrowings.

Commitments are due at 6 a.m. ET on Feb. 19, the source added.

Atnahs is a Basildon, U.K.-based specialty pharmaceutical business focused on the acquisition, development and marketing of mature branded medicines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.